<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100602</url>
  </required_header>
  <id_info>
    <org_study_id>2016063011442779</org_study_id>
    <nct_id>NCT05100602</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients</brief_title>
  <official_title>Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genetron Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genetron Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trail is to evaluate the performance of Genetron TERT PCR Kit in Glioma&#xD;
      patients using real-time PCR method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial follows the principle of synchronous blinding. The enrolled cases are coded, and&#xD;
      the enrolled samples are detected with the Genetron TERT PCR Kit and Sanger sequencing&#xD;
      method. The results were determined independently according to the cutoff values or&#xD;
      interpretation requirements provided by each method.Combined with the results of&#xD;
      clinicopathological classification, the incidence of C228T and C250T mutations of TERT&#xD;
      promoter genes in different subtypes was counted to evaluate the clinical application&#xD;
      performance of the Genetron TERT PCR Kit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2016</start_date>
  <completion_date type="Actual">December 8, 2016</completion_date>
  <primary_completion_date type="Actual">September 22, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the Genetron TERT PCR Kit</measure>
    <time_frame>3 months</time_frame>
    <description>The main purpose of this study is: by evaluating the Genetron TERT PCR Kit to compare the results of the Sanger sequencing method, and to calculate the coincidence rate and consistency of the two methods.</description>
  </primary_outcome>
  <enrollment type="Actual">1192</enrollment>
  <condition>Glioma, Malignant</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Enroll cases in strict accordance with the requirements of the study&#xD;
&#xD;
          2. The remaining samples after routine clinical testing&#xD;
&#xD;
          3. The collection and processing of samples meet the requirements of standard laboratory&#xD;
             operations and product instructions&#xD;
&#xD;
          4. The relevant information of the sample is complete, including sample number, gender,&#xD;
             age, and possible clinical diagnosis information&#xD;
&#xD;
          5. Each sample must have HE staining results (hematoxylin-eosin staining)&#xD;
&#xD;
          6. Pathological examination diagnosed as glioma, other brain tumors or normal tissues&#xD;
&#xD;
          7. Number of samples: 10 pieces of each sample with a thickness of 10Î¼m, and the tumor&#xD;
             content is not less than 50%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The sample information is not complete&#xD;
&#xD;
          2. Severely contaminated samples&#xD;
&#xD;
          3. Samples that do not meet the requirements of sample collection and processing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

